LOS ANGELES, April 10, 2018 -- Investor’s Business Daily (IBD), a leading financial news and research organization, today announced that several of its stock lists are performing significantly better than the S&P 500, which is widely considered one of the market’s key benchmarks for stock returns. IBD Sector Leaders, IBD 50, and IBD Big Cap 20 have all posted higher returns over the last three-month, six-month, and 12-month periods, as well as Year-to-Date.
“The performance of our stock lists helped our subscribers take full advantage of the strength of the market over the past year,” said Chris Gessel, IBD’s Chief Content Officer. “Our market analysis and sell rules have helped them preserve those gains as the market gyrates through this current correction. Based on our proprietary data and CAN SLIM Investing System, investors can make wise decisions based on their specific strategies and priorities.”
IBD’s CAN SLIM Investing System was developed when legendary investor and IBD founder William J. O’Neil compiled a database of every stock traded in the US since the 1880’s. After studying over 100 years’ worth of data, filtering out the best performing stocks, O’Neil noted that winning companies had the same seven traits in common before they made huge gains. These traits, and this data-first approach to investing, serve as the foundation for all IBD products and stock lists.
IBD Sector Leaders
The Sector Leaders index is IBD’s most stringent and powerful stock list. Sector Leaders highlights the best stocks in IBD’s 33 sectors. All Sector Leaders show outstanding earnings and sales growth in recent quarters and are strong across many other fundamental and price-performance metrics.
Compared to the S&P 500:
- Over the last three months: Sector Leaders was up 7.93% compared to -0.74% for the S&P
- Over the last six months: Sector Leaders was up 16.39% compared to 5.21% for the S&P
- Over the last year: Sector Leaders was up 38.04% compared to 11.52% for the S&P
- Since the beginning of 2018: Sector Leaders was up 9.55% compared to -1.22% for the S&P.
IBD 50
IBD 50 is the flagship list of leading growth stocks. It shows investors 50 companies that demonstrate strong relative price strength and top-notch fundamentals. These new and innovative stocks have historically far outperformed the S&P 500.
Compared to the S&P 500:
- Over the last three months: IBD 50 was up 5.27% while the S&P performed at -0.74%
- Over the last six months: IBD 50 was up 15.64% compared to 5.21% for the S&P
- Over the last year: IBD 50 was up 31.07% compared to 11.52% for the S&P
- Since the beginning of 2018: IBD 50 was up 6.17% compared to -1.22% for the S&P.
IBD Big Cap 20
IBD Big Cap 20 uncovers top-rated, large-cap growth stocks. Big Cap 20 companies can deliver outsize gains without the volatility of smaller growth stocks. Examining performance of the IBD Big Cap 20 next to the S&P 500, one will find:
- Over the last three months: IBD Big Cap 20 was up 2.21% while the S&P performed at -0.74%
- Over the last six months: IBD Big Cap 20 was up 9.91% compared to 5.21% for the S&P
- Over the last year: IBD Big Cap 20 was up 16.46% compared to 11.52% for the S&P
- Since the beginning of 2018: IBD Big Cap 20 was up 2.69% compared to -1.22% for the S&P.
Performance data across each product was compared through March 29, 2018.
In addition to identifying market trends, IBD delivers analysis to investors in ways that match their lifestyle and preferences. IBD produces compelling editorial content, reports, and webinars, and has developed a user-friendly mobile app that includes several features that cannot be found anywhere else. To learn more about all that IBD offers, gain access to industry-leading market indexes, please visit www.investors.com.
ABOUT INVESTOR'S BUSINESS DAILY (IBD)
Investor’s Business Daily is a leading financial news and research organization recognized for providing stock screens, comparative performance ratings, and unique commentary helping investors zero in on top performing growth stocks. IBD provides the buy rules and sell rules to properly make trading decisions that will minimize your risk and maximize your potential profit. IBD offers individual and professional investors a comprehensive lineup of print and online products, all based on a powerful investing system that has dramatically outperformed the S&P 500.
IBD’s website, Investors.com, offers tools, analysis and research for investors of all levels: IBD University learning center, IBD TV market videos and the IBD Stock Checkup®. IBD also hosts popular investment workshops and provides Home Study programs based on the top-performing growth strategy, CAN SLIM. IBD was founded April 9, 1984 by William J. O'Neil, who also originated CAN SLIM.
© 2018 Investor's Business Daily, Inc. All rights reserved. Investor's Business Daily, IBD, CAN SLIM and their corresponding logos are registered trademarks of Investor's Business Daily, Inc.
For Editorial Contact:
Stephanie Gnibus
GMK Communications for IBD
[email protected]


ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
FTC Questions Apple News Over Alleged Bias Against Conservative Media
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 



